Acadia Pharmaceuticals Inc. announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company?s Executive Management Committee. Mr. Kildani joins Acadia most recently from Halozyme Therapeutics, where he served as Vice President, Investor Relations and Corporate Communications and helped guide the company?s transition from early drug development stage to a profitable biopharmaceutical company.

Prior to Halozyme, Al oversaw investor relations and business development at Vital Therapies Inc., and investor relations at Hologic Inc. and Gen-probe Incorporated. Prior to his transition to the life sciences industry, Al spent over a dozen years on Wall Street serving as an analyst and portfolio manager at Stark Investments, and previously as a sell-side analyst with C.E. Unterberg, Towbin and Pacific Growth Equities LLC. Mr. Kildani earned a bachelor?s degree in Economics and Finance from Boston College.